Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 31 31 97 53
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
Manwiththeplan
Manwiththeplan Dec. 4 at 7:42 PM
$EVAX
0 · Reply
Manwiththeplan
Manwiththeplan Dec. 3 at 6:36 PM
$EVAX (27) Plaatsen | LinkedIn https://share.google/nk526zKB1vYQ0zDY4
1 · Reply
Manwiththeplan
Manwiththeplan Dec. 2 at 6:04 PM
$EVAX
1 · Reply
AndreaRR
AndreaRR Nov. 28 at 5:20 PM
$EVAX It would be a fantastic buyout by Merck, which has an urgent need for new multi-billion dollar drugs, due to the Keytruda patent expiration in 2027.
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 26 at 8:02 PM
$EVAX i almost doubled my position yesterday. I am hoping for a deal.
1 · Reply
Tigerz11
Tigerz11 Nov. 25 at 6:23 AM
$EVAX Dr. Helen Tayton-Martin is not just a scientist; she is a dealmaker. • Her Background: She spent 17 years at Adaptimmune, where she was Chief Business Officer. Her specialty is negotiating strategic partnerships with big pharma (she led deals with GSK, Genentech, and Astellas). • The Timing: You don't hire a "Deal Specialist" CEO just to run day-to-day lab operations. You hire her to close a contract. Starting her right before the ASH conference (Dec 6) suggests she is there to shake hands, not just watch slides.
1 · Reply
FurrrMom
FurrrMom Nov. 23 at 6:54 PM
$LBGJ oversold and coiled for a pounce. I really like this. Similar setup to other recent IPOs that ran from under a dollar to over $10. Accumulating. I also like $EVAX here. ~$14 potential and a pipeline full of potential catalysts. I’m bullish on $TMC even up here. 30% plus upside if deep-sea mining really ramps up. Watching for potential swing entry. Loving $PDYN for those recent insider buys. I won't call it a hard watch but it's definitely worth reading some filings. GLTA!
1 · Reply
ap20
ap20 Nov. 22 at 5:31 PM
$EVAX any concerns with the European Investment Bank selling shares? I’m not familiar with them and how they do things. Thanks.
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 22 at 4:50 PM
$EVAX my PT is 20 in the coming months. If there is not a significant partnership in the next 6 months i ll be reducing my position
0 · Reply
mikesterz7
mikesterz7 Nov. 22 at 11:42 AM
$EVAX PT 10
0 · Reply
Latest News on EVAX
Evaxion announce 2026 financial calendar

Nov 12, 2025, 8:00 AM EST - 22 days ago

Evaxion announce 2026 financial calendar

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 7, 2025, 5:10 PM EST - 27 days ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:56 PM EST - 4 weeks ago

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Evaxion announces business update and third quarter 2025 financial results

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Evaxion announces business update and third quarter 2025 financial results

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 9:05 AM EDT - 4 weeks ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 4 weeks ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 27, 2025, 8:00 AM EDT - 5 weeks ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Oct 22, 2025, 5:13 PM EDT - 6 weeks ago

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 17, 2025, 8:15 AM EDT - 6 weeks ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 13, 2025, 8:00 AM EDT - 7 weeks ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 8, 2025, 8:12 AM EDT - 2 months ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 2 months ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion A/S - Special Call

Sep 25, 2025, 11:07 AM EDT - 2 months ago

Evaxion A/S - Special Call

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Sep 25, 2025, 7:00 AM EDT - 2 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:29 PM EDT - 3 months ago

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Aug 11, 2025, 8:00 AM EDT - 4 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 25, 2025, 9:00 AM EDT - 4 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 11, 2025, 8:00 AM EDT - 5 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 5 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 6 months ago

Evaxion receives grant funding to design new polio vaccine

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 10:43 AM EDT - 6 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 6 months ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 26, 2025, 8:47 AM EDT - 6 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 6 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 7 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 8 months ago

Evaxion to present at World Vaccine Congress

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 11:21 AM EDT - 8 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 9 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 10 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 10 months ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 11 months ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 11 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces completion of ADS ratio change

Jan 14, 2025, 4:05 PM EST - 11 months ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Jan 10, 2025, 8:00 AM EST - 11 months ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 1 year ago

Evaxion announces plan to implement ADS ratio change

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Evaxion Biotech Partners With Merck To Expand Vaccine Development

Sep 26, 2024, 10:53 AM EDT - 1 year ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Evaxion significantly expands vaccine development collaboration with MSD

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion significantly expands vaccine development collaboration with MSD

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 11:43 AM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Manwiththeplan
Manwiththeplan Dec. 4 at 7:42 PM
$EVAX
0 · Reply
Manwiththeplan
Manwiththeplan Dec. 3 at 6:36 PM
$EVAX (27) Plaatsen | LinkedIn https://share.google/nk526zKB1vYQ0zDY4
1 · Reply
Manwiththeplan
Manwiththeplan Dec. 2 at 6:04 PM
$EVAX
1 · Reply
AndreaRR
AndreaRR Nov. 28 at 5:20 PM
$EVAX It would be a fantastic buyout by Merck, which has an urgent need for new multi-billion dollar drugs, due to the Keytruda patent expiration in 2027.
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 26 at 8:02 PM
$EVAX i almost doubled my position yesterday. I am hoping for a deal.
1 · Reply
Tigerz11
Tigerz11 Nov. 25 at 6:23 AM
$EVAX Dr. Helen Tayton-Martin is not just a scientist; she is a dealmaker. • Her Background: She spent 17 years at Adaptimmune, where she was Chief Business Officer. Her specialty is negotiating strategic partnerships with big pharma (she led deals with GSK, Genentech, and Astellas). • The Timing: You don't hire a "Deal Specialist" CEO just to run day-to-day lab operations. You hire her to close a contract. Starting her right before the ASH conference (Dec 6) suggests she is there to shake hands, not just watch slides.
1 · Reply
FurrrMom
FurrrMom Nov. 23 at 6:54 PM
$LBGJ oversold and coiled for a pounce. I really like this. Similar setup to other recent IPOs that ran from under a dollar to over $10. Accumulating. I also like $EVAX here. ~$14 potential and a pipeline full of potential catalysts. I’m bullish on $TMC even up here. 30% plus upside if deep-sea mining really ramps up. Watching for potential swing entry. Loving $PDYN for those recent insider buys. I won't call it a hard watch but it's definitely worth reading some filings. GLTA!
1 · Reply
ap20
ap20 Nov. 22 at 5:31 PM
$EVAX any concerns with the European Investment Bank selling shares? I’m not familiar with them and how they do things. Thanks.
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 22 at 4:50 PM
$EVAX my PT is 20 in the coming months. If there is not a significant partnership in the next 6 months i ll be reducing my position
0 · Reply
mikesterz7
mikesterz7 Nov. 22 at 11:42 AM
$EVAX PT 10
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 22 at 11:01 AM
$EVAX why would a new CEO start 24th of a month? And 4 days for thanksgiving and 1 month before christmas? She was hired as a boardmember 6 months ago. I think she will announce a partnership before christmas
2 · Reply
Manwiththeplan
Manwiththeplan Nov. 22 at 10:57 AM
$EVAX When you combine: the unusual CEO start date, the timing of capital raises, the restoration of Nasdaq compliance, the MSD option execution, the pipeline expansion, and warrant exercise activity, …it forms a very consistent pattern seen in small-cap biotechs right before they announce: a new partnership, a co-development deal, or an out-licensing agreement.
1 · Reply
Manwiththeplan
Manwiththeplan Nov. 21 at 5:37 PM
$EVAX new CEO will start monday
0 · Reply
ap20
ap20 Nov. 21 at 1:13 AM
$EVAX Rookie here. Very intriguing.. really like the small float and doing multiple good things. Bought a few yesterday and caught the high of the day today…arghh. Seems like a good play. Good luck everybody.
1 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Nov. 20 at 3:03 PM
$EVAX I think this will be a 100%+ runner at some point before the end of the New Year. Why? Long cash runway(late '27), new leadership, positive vaccine data, and the biggest catalyst in my opinion is the realization of AI in the healthcare realm. Small market cap means potentially a buyout down the road as well. I think 5 is a great entry price. My average is 9, so I'm down but not upset. I have a 3-5 year timeframe so not selling anytime soon. Good luck and please do your own due diligence on this one.
1 · Reply
baldaldo
baldaldo Nov. 20 at 2:39 PM
$EVAX Ugh. Still no volume...
1 · Reply
MT25
MT25 Nov. 20 at 2:16 PM
$EVAX OMG they are coocking!🧑‍🍳
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 20 at 1:18 PM
$EVAX their pipeline is exploding. Now the deals.
0 · Reply
Lenni_D
Lenni_D Nov. 20 at 1:04 PM
$EVAX https://evaxion.ai/investors/press-releases/?press_release_id=10791
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 20 at 1:01 PM
$EVAX Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
0 · Reply
Manwiththeplan
Manwiththeplan Nov. 12 at 12:56 PM
$EVAX waiting patiently on a buy out bid of 1 billion.
4 · Reply
Manwiththeplan
Manwiththeplan Nov. 10 at 8:55 PM
$EVAX new CEO will start 24th of november. I dont expect any deals till thenor soon after. I hope first months of 26
0 · Reply